We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New figures released by the Association of the British Pharmaceutical Industry revealed that the balance of trade in pharmaceuticals -- last year the highest of any sector in British industry -- has shown a decline, with the UK coming at the bottom of the league on prescribing modern treatments.
It is remarkable that among the major public health problems associated with the use of substandard pharmaceutical excipients in recent years, the majority have come about not because of errors in manufacturing, but errors in distribution.
Israeli-based drug developer Pharmos has been awarded a grant of $1.3 million from the Israeli Office of the Chief Scientist (OCS) to fund the development of drug candidates from the company's CB2-selective platform of synthetic cannabinoids.
New research showing the benefits of novel drug therapies for pulmonary arterial hypertension (PAH), a serious lung disease, was presented at the 26th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), held recently in Madrid, Spain.
U.S.-based drugmaker Wyeth has purchased an additional 10 percent stake in Wyeth KK (WKK), its Japanese-based joint venture with Takeda Pharmaceutical.
GlaxoSmithKline and Adolor Corporation announced today that GSK has completed enrollment of the Phase 3 clinical program to evaluate the efficacy and safety of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal adverse events caused by opioids used for persistent non-cancer pain.
Mistral Pharma Inc. announces today that, in accordance with its stock option plan, the board of directors of Mistral has granted after the close of markets yesterday stock options to purchase 1,968,255 common shares of Mistral at an exercise price of $ 0.10 per share to certain officers of Mistral.